STAT3 and head and neck cancer: A phase I study of Stat3 inhibitor in solid tumors at M D Anderson Cancer Center (NCT00955812) and a phase 0 study of a Stat3 decoy in head and neck cancer was recently completed (NCT00696176) (www.clinicaltrials.gov)